Breakthroughs in AI and multi-omics for cancer drug discovery: A review

Eur J Med Chem. 2024 Dec 15:280:116925. doi: 10.1016/j.ejmech.2024.116925. Epub 2024 Oct 4.

Abstract

Cancer is one of the biggest medical challenges we face today. It is characterized by abnormal, uncontrolled growth of cells that can spread to different parts of the body. Cancer is extremely complex, with genetic variations and the ability to adapt and evolve. This means we must continuously pursue innovative approaches to developing new cancer drugs. While traditional drug discovery methods have led to important breakthroughs, they also have significant limitations that make it difficult to efficiently create new, cost-effective cancer therapies. Integrating computational tools into the cancer drug discovery process is a major step forward. By harnessing computing power, we can overcome some of the inherent barriers of traditional methods. This review examines the range of computational techniques now being used, such as molecular docking, QSAR models, virtual screening, and pharmacophore modeling. It looks at recent advances in areas like machine learning and molecular simulations. The review also discusses the current challenges with these technologies and envisions future directions, underscoring how transformative these computational tools can be for creating targeted, new cancer treatments.

Keywords: Anticancer drug discovery; Computer-aided drug design (CADD); Deep learning; Multi-omics; Quantitative structure-activity relationship (QSAR).

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Artificial Intelligence
  • Drug Discovery*
  • Humans
  • Multiomics
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Quantitative Structure-Activity Relationship

Substances

  • Antineoplastic Agents